Kannalife, Inc. (“Kannalife”), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by Sports Illustrated as a “super-CBD” and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy”.
Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”), Chronic Traumatic Encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy (“CIPN”). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
Our scientific team, comprised of dedicated professionals, clinicians and bio-chemists, all have a strong background in phyto-medical, biological and pharmaceutical sciences with a long track record of successfully developing drugs from plant sources that are complex in nature and structure. The team collectively has over 75+ years of research and pharmaceutical experience and have been published in over 300 notable journal publications and hold inventorships in over 65 patents.
Our goal is to become a profitable and socially responsible company that develops treatments and seeks to improve the quality of life of patients with neurodegenerative diseases.